Evaluation of Quality of Life and Its Influencing Factors After VA-ECMO in Refractory Cardiac Arrest Based on SF-36 Score : A Grenoble Cohort Study From 2006 Through 2018

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04601896

Acronym

AQUA

Enrollment

Registered

2020-10-26

Start date

2020-10-16

Completion date

2021-04-27

Last updated

2021-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ExtraCorporeal Membrane Oxygenation (ECMO), Refractory Cardiac Arrest

Keywords

ExtraCorporeal Membrane Oxygenation (ECMO), Refractory Cardiac Arrest, Quality life assessement (SF36 QUESTIONNAIRE)

Brief summary

If the ExtraCorporeal Membrane Oxygenation (ECMO) improves survival in the management of refractory cardiac arrest (RCA), this technique is still an invasive technique, not devoid of complications and requiring intensive care that can have serious consequences for patients. If the studies so far show an acceptable quality of life post ECMO in refractory cardiac arrest, the study looks about the quality of life of our patients in Grenoble who survived a refractory cardiac arrest between 2006 and 2018 at the hospital university Grenoble Alps and the factors influencing this quality of life.

Interventions

OTHERSF36 questionnaire via telephone interview

SF36 questionnaire via telephone interview

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult \>18 years * Admission to intensive care unit after a Refractory Cardiac Arrest * Hemodynamic instability after resumption of spontaneous cardiac activity. * Non-opposition of the patient or his relatives * Admission to intensive care unit From 2006 Through 2018

Exclusion criteria

* ECMO for hypothermia or drug intoxication. * Comorbidity contraindicated the ECMO * Patients dead before hospital discharge

Design outcomes

Primary

Measure	Time frame	Description
Global quality of life score	Through study completion, an average of 3 months	Items from the SF36 (Short Form 36) survey

Secondary

Measure	Time frame	Description
Live patients characteristics description	Through study completion, an average of 3 months	Demographic and clinical retrospective data collection
Vital status	Through study completion, an average of 3 months	Deed/Lived
Quality of life score related at live patients characteristics description	Through study completion, an average of 3 months	Items from the SF36 (Short Form 36) survey matched with live patients characteristics description
Quality of life score comparison	Through study completion, an average of 3 months	Items from the SF36 (Short Form 36) survey compared between the 2 groups ( RCA with /without ECMO) admitted from january 2015 and december 2018

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026